Anbio Biotechnology, a leader in in-vitro diagnostic technologies, announced its participation in three international exhibitions in May 2025: EuroMedLab in Brussels, AVA Conference in Sydney, and ...

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology (NNNN) has announced the launch of its Chikungunya IgM/IgG Rapid Test, ...

View Anbio Biotechnology Class A NNNN stock quote prices, financial information, real-time forecasts, and company news from CNN.

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NNNN), a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, ...

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is ...

09:59 EDT Anbio Biotechnology (NNNN) trading halted, volatility trading pause Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover ...

Overview: Anbio Biotechnology specializes in providing in vitro diagnostics (IVD) products across various global markets and has a market capitalization of $1.20 billion. Operations: Anbio generates ...

Detailed price information for Anbio Biotechnology Cl A (NNNN-Q) from The Globe and Mail including charting and trades.

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 ...